Anavex Life Sciences Corp.
AVXL
and Strategy Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system ( CNS ) diseases with high unmet need. We analyze genomic data from clinical trials to identify biomarkers, which we use in the analysis of our clinical trials.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$13M
▼ -7.8% YoY
Op. Margin
–
ROIC
-12.05%
▼ -5.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$29M
▼ -26.7% YoY
Op. Cash Flow (TTM)
-$29M
▼ -26.7% YoY
Net Debt
-$118M
Net Cash Position
Cash & Equiv.
$118M
Continue Research
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with AVXL
Held by ETFs
AVXL is in 9 US ETFs. The largest of them, with AVXL's weight in each:
Anavex Life Sciences (AVXL) in two numbers
Questions about Anavex Life Sciences
Does Anavex Life Sciences (AVXL) pay a dividend?
No. Anavex Life Sciences (AVXL) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 28 Aug 2026 (period ending 30 Jun 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in AVXL's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing AVXL
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.